Auranofin and iodoquinol as promising repurposing drugs against filamentous fung...

연구 요약

Auranofin and iodoquinol as promising repurposing drugs against filamentous fungi: antifungal activity and cellular alterations.

Microbiology spectrum 학술지에 발표된 이 연구는 Xisto MIDdS, Rollin-Pinheiro R, da Rosa PCM 외 연구팀이 수행하였습니다.

이 연구는 'Auranofin and iodoquinol as promising repurposing drugs against filamentous fungi: antifungal activity and cellular alterations.'에 대한 과학적 분석을 제공합니다.

핵심 내용

Opportunistic fungal infections have become an increasing health threat, particularly in immunocompromised individuals, due to their high virulence, biofilm-forming capacity, and resistance to conventional antifungals. Given the limited therapeutic arsenal, drug repurposing represents a promising strategy for antifungal discovery. This study evaluated the antifungal activity and mechanisms of auranofin and iodoquinol against filamentous fungi listed as World Health Organization (WHO) priority pathogens, including Aspergillus fumigatus, Fusarium oxysporum, Scedosporium boydii, Lomentospora prolificans, Rhizopus oryzae, Mucor velutinosus, and Cunninghamella sp. Although Aspergillus flavus is not included in the WHO priority list, it was included in this study due to its clinical relevance as a major cause of aspergillosis and fungal rhinosinusitis. Auranofin displayed fungicidal activity against Aspergillus spp., L. prolificans, S. boydii, and R. oryzae, while iodoquinol exhibited potent but mainly fungistatic effects, with minimum inhibitory concentration values ranging from 0.625 to 20 µM. Both compounds inhibited early growth and reduced preformed biofilms by over 50% in biomass and metabolic activity. Stress susceptibility and fluorescence assays indicated that auranofin interferes with lipid homeostasis, cell wall integrity, and oxidative stress responses, whereas iodoquinol alters membrane lipids, mannose, and chitin distribution, suggesting multitarget surface effects. Scanning electron microscopy revealed consistent ultrastructural alterations, including hyphal deformation and increased extracellular matrix deposition in A. fumigatus and F. oxysporum treated with sub-inhibitory drug concentrations, corroborating the observed cellular stress responses. Drug interaction assays demonstrated additive or synergistic effects with voriconazole and amphotericin B, but not with posaconazole. Overall, auranofin and iodoquinol exhibit broad-spectrum antifungal activity, disrupt fungal morphology and physiology, and represent promising repurposed candidates for developing novel combination therapies against refractory mycoses.IMPORTANCEMycoses caused by opportunistic fungi are an increasingly public health problem, particularly in immunocompromised individuals, due to their high virulence and resistance to conventional antifungals. The World Health Organization's priority fungal pathogens list points out a variety of filamentous fungi, such as Aspergillus fumigatus, A. flavus, Fusarium oxysporum, Scedosporium boydii, Lomentospora prolificans, Rhizopus oryzae, Mucor velutinosus, and Cunninghamella sp. Given the limited therapeutic arsenal to combat them, drug repurposing represents a promising strategy for antifungal discovery. The present study evaluated the antifungal activity and some cellular alterations caused by auranofin and iodoquinol, which are already available in clinical settings to treat rheumatoid arthritis and infections by amoeba, respectively. The data presented in the study revealed that both drugs display a wide spectrum of action against different fungal pathogens, as well as contribute to highlight the potential of them as repurposing drugs to be investigated as alternatives for the treatment of mycoses.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41757906)